Company: RGBP
Filing Date: 2025-09-08
Form Type: 253G1
Source: 0001641172-25-026822
Chunk: 108

Company: Regen BioPharma Inc
Filing Date: 2025-09-08
Form: 253G1
Chunk 108
---
                                              |     |                   |        - |   |     |                   |          |   |
| Increase ( Decrease) in Common Stock issued for cash                             |     |                   |          |   |     |                   |  212,297 |   |
| Net Cash Provided by (Used in) Financing Activities                              |     |                   |   65,799 |   |     |                   |  165,797 |   |
| Net Increase (Decrease) in Cash                                                  |     |                   |     (581 | ) |     |                   |    3,460 |   |
| Cash at Beginning of Period                                                      |     |                   |      716 |   |     |                   |  121,037 |   |
| Cash at End of Period                                                            |     | $                 |      135 |   |     | $                 |  124,497 |   |
| Supplemental Disclosure of Noncash investing and financing activities:           |     |                   |          |   |     |                   |          |   |
| Preferred Shares Issued for Debt                                                 |     |                   |        - |   |     |                   |          |   |
| Cash Paid for Interest                                                           |     |                   |        - |   |     |                   |          |   |
| Common shares Issued for Interest                                                |     |                   |        - |   |     |                   |          |   |
| Preferred Shares issued for Interest                                             |     |                   |        - |   |     |                   |          |   |

<div align='center'>The Accompanying Notes are an Integral Part of These
Financial Statements</div>

| 88 |

<div align='center'>REGEN BIOPHARMA, INC.

Notes to Condensed Consolidated Financial Statements

As of December 31, 2024</div>

These Notes have been retroactively adjusted to reflect
a 1 for 1500 reverse stock split of all issued series of stock effective as of March 6, 2023

1. ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The Company was organized April 24, 2012 under the
laws of the State of Nevada

The Company intends to engage primarily in the development
of regenerative medical applications which we intend to license from other entities up to the point of successful completion of Phase
I and or Phase II clinical trials after which we would either attempt to sell or license those developed applications or, alternatively,
advance the